Skip to Content
Nov 10 2022
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST Data show that radiotherapy-activated NBTXR3 followed by anti-PD-1 was feasible and well tolerated in the complete dose escalation part of the Company’s phase 1 immunotherapy study with a recommended phase 2 dose established at
Nov 08 2022
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS , Nov. 08, 2022 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code:
Oct 31 2022
PARIS and Cambridge, Mass. , Oct. 31, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent
Oct 10 2022
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS --(BUSINESS WIRE)--Oct. 10, 2022-- Regulatory News : Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext